WO2022188850A1 - 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 - Google Patents
包含己酸羟孕酮的抗肿瘤联合制剂及其用途 Download PDFInfo
- Publication number
- WO2022188850A1 WO2022188850A1 PCT/CN2022/080275 CN2022080275W WO2022188850A1 WO 2022188850 A1 WO2022188850 A1 WO 2022188850A1 CN 2022080275 W CN2022080275 W CN 2022080275W WO 2022188850 A1 WO2022188850 A1 WO 2022188850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- therapeutic agent
- additional therapeutic
- hydroxyprogesterone caproate
- tumor
- Prior art date
Links
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 title claims abstract description 33
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000000259 anti-tumor effect Effects 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 27
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 15
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 230000001965 increasing effect Effects 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- -1 ICOS Proteins 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 7
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 102100038078 CD276 antigen Human genes 0.000 claims description 6
- 101710185679 CD276 antigen Proteins 0.000 claims description 6
- 108010065524 CD52 Antigen Proteins 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 6
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 6
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 6
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 208000037819 metastatic cancer Diseases 0.000 claims description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 229950007712 camrelizumab Drugs 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 230000000174 oncolytic effect Effects 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229940121497 sintilimab Drugs 0.000 claims description 4
- 238000002626 targeted therapy Methods 0.000 claims description 4
- 229950007123 tislelizumab Drugs 0.000 claims description 4
- 229940121514 toripalimab Drugs 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 238000001794 hormone therapy Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010070308 Refractory cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
- 238000009094 second-line therapy Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- DBPWSSGDRRHUNT-SJFWLOONSA-N (8r,9s,10r,13s,14s,17s)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-SJFWLOONSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to a pharmaceutical composition for treating tumors and a method for treating tumors, in particular to a pharmaceutical composition comprising enhancing the effect of a tumor therapeutic agent by improving the tumor microenvironment and a method for treating tumors by combining medication.
- Malignant tumor is a major disease that seriously threatens human health.
- Conventional treatment methods include surgery, radiotherapy, chemotherapy and targeted therapy, but the effect on advanced tumors is very limited, and there are problems of large toxic side effects and poor tolerance.
- tumor immunotherapy has achieved remarkable clinical effects. It is a treatment method that activates the body's own immune system to fight tumors. It is currently the most potential treatment method for curing malignant tumors. Therefore, tumor immunotherapy was selected for the Nobel Prize in Physiology or Medicine in 2018.
- the tumor microenvironment is an important aspect of cancer biology that contributes to tumorigenesis, tumor progression, and response to therapy.
- the cells and molecules of the immune system are fundamental components of the tumor microenvironment.
- the composition and characteristics of the tumor microenvironment vary widely and are important for determining anti-tumor immune responses.
- certain cells of the immune system including natural killer cells, dendritic cells (DCs), and effector T cells, are able to drive powerful antitumor responses.
- tumor cells often induce an immunosuppressive microenvironment that favors the development of immunosuppressive populations of immune cells, such as myeloid-derived suppressor cells and regulatory T cells.
- immune checkpoint inhibitors can play an anti-tumor effect by blocking the immunosuppressive signals in the tumor microenvironment and restoring the function of immune cells.
- the most in-depth and mature immune checkpoints are programmed cell death receptor 1 (PD-1), programmed death ligands 1 and 2 (PD-L1/L2), cytotoxic T cell antigen 4 ( CTLA-4), as well as lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin mucin 3 (TIM-3), T cell immunoglobulin and ITIM domain protein (TIGIT), and T cell activation V region Immunoglobulin Inhibitors (VISTA) et al (Randoph J. Nolle, Science, 2020).
- PD-1 programmed cell death receptor 1
- PD-L1/L2 programmed death ligands 1 and 2
- CTLA-4 cytotoxic T cell antigen 4
- LAG-3 lymphocyte activation gene 3
- TIM-3 T cell immunoglobulin mucin 3
- TAGIT T cell immunoglobulin and
- PD-1 and/or PD-L1 are highly expressed in the majority of tumor-infiltrating lymphocytes (TILs) from many different tumor types and suppress local effector immune responses including lung, liver, ovarian, cervical, cancer, skin cancer, colon cancer, glioma, bladder, breast, kidney, esophagus, stomach, oral squamous cell carcinoma, urothelial cell carcinoma and pancreatic cancer, and tumors of the head and neck .
- TILs tumor-infiltrating lymphocytes
- PD-1 and/or PD-L1 antibodies can block the binding of PD-L1 on tumor cells to the inhibitory receptor PD-1 on the surface of activated T cells, thereby activating tumor-specific T cells and rebuilding the immune system against tumor cells. killing effect.
- PD-1 antibodies are only about 20% of clinical response rate.
- PD-1 antibody not only PD-1 antibody, but also other antibodies and even various tumor therapeutic agents have shown great differences in clinical practice from in vitro tests.
- the microenvironment makes it difficult for drugs to reach the target, and it is difficult for immune cells to enter the tumor tissue to kill cancer cells.
- 17 ⁇ -Hydroxypregn-4-ene-3,20-dione caproate also known as hydroxyprogesterone caproate, 17-hydroxyprogesterone caproate, 17-HPC, 17-OHPC, OHPC, English name: Hydroxyprogesterone Caproate, CAS No.: 630-56-8, is clinically used to treat habitual abortion, irregular menstruation, endometriosis, functional uterine bleeding, etc.
- a pharmaceutical composition comprising hydroxyprogesterone caproate and another additional therapeutic agent for treating tumors.
- another additional therapeutic agent for the treatment of tumors is selected from the group consisting of chemotherapeutic agents, targeted therapy agents, hormone therapy agents, cell therapy agents, oncolytic viral agents or antibodies, especially immune checkpoint inhibitors.
- the immune checkpoint inhibitor is selected from PD-L1, PD-1, PD-L2, CTLA-4, LAG3, B7-H3, KIR, CD137, PS, TFM3, CD52, CD30, CD20, CD33 , CD27, OX40, GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, SLAM or a combination of inhibitors; preferably, the immune checkpoint inhibitor is a single A cloned antibody, particularly preferably a monoclonal antibody directed against PD-1 or PD-L1.
- the additional therapeutic agent is selected from atezolizumab, avelumab, durvalumab, camrelizumab, cilimumab, ipilimumab, nivolumab , Pembrolizumab, Sintilimab, Tislelizumab, Toripalimab, Tislimumab, RC98.
- antineoplastic drug comprising the above-mentioned pharmaceutical composition comprising hydroxyprogesterone caproate and another additional therapeutic agent for treating tumors, and optionally one or more Pharmaceutically acceptable excipients.
- the dosage form of the antitumor drug is selected from injections, oral preparations or external preparations; injections or oral preparations are preferred; injections are particularly preferred.
- the injection is selected from injection or powder injection; the oral preparation is selected from tablet, solution, capsule, powder, pill, granule, syrup, suspension or oral sustained and controlled-release preparation; the external preparation is selected from ointment , spray or patch.
- the additional therapeutic agent is present in amounts ranging from 10% to 100% of the therapeutically effective amount when used alone.
- the content of each tablet/dose of hydroxyprogesterone caproate is 100-1000 mg
- the content of each tablet/dose of hydroxyprogesterone caproate is (100-1000 mg)/m
- the content of each tablet/dose of hydroxyprogesterone caproate is n ⁇ (100-1000 mg).
- the pharmaceutically acceptable adjuvants are selected from pharmaceutically acceptable solvents, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents , osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integration agents, penetration enhancers, pH adjusters, buffers , plasticizers, surfactants, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculants, filter aids, release retarders, polymer framework materials and film-forming materials at least one of.
- the invention provides a method of increasing the number of tumor infiltrating lymphocytes (TILs) in need, comprising providing hydroxyprogesterone caproate to a subject.
- TILs tumor infiltrating lymphocytes
- its TIL population comprises a population of CD8+ T cells, CD4+ T cells, B cells, natural killer (NK) cells, dendritic cells (DC), M1 macrophages or a combination thereof, preferably expressing a TH1 phenotype of T cells.
- TILs are increased in the tumor microenvironment (TME) and/or in tumor tissue.
- the invention provides a method of treating cancer in a subject in need thereof, comprising providing hydroxyprogesterone caproate to the subject.
- it includes providing the subject with an additional therapeutic agent other than hydroxyprogesterone caproate to treat cancer.
- its additional therapeutic agent is selected from chemotherapeutic agents, targeted therapy agents, hormone therapy agents, cell therapy agents, oncolytic viral agents or antibodies.
- the additional therapeutic agent is selected from immunotherapeutic agents.
- the additional therapeutic agent is selected from immune checkpoint inhibitors.
- the immune checkpoint inhibitor is selected from PD-L1, PD-1, PD-L2, CTLA-4, LAG3, B7-H3, KIR, CD137, PS, TFM3, CD52, CD30, CD20, CD33, Inhibitors of CD27, OX40, GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, SLAM, preferably against PD-1, PD-L2, CTLA-4, LAG3, B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,SLAM A monoclonal antibody or a combination thereof, particularly preferably a monoclonal antibody against PD-L1 or PD-1.
- the additional therapeutic agent is selected from atezolizumab, avelumab, durvalumab, camrelizumab, cilimumab, ipilimumab, nivolumab anti, pembrolizumab, sintilimab, tislelizumab, toripalimab, temslimumab, or RC98.
- the subject has higher PD-L1 or PD-1 expression.
- it is administered as a first- or second-line therapy.
- its hydroxyprogesterone caproate may be administered to the subject prior to, concurrently with, or subsequent to administration of the additional therapeutic agent.
- the subject thereof has primary or metastatic cancer.
- the cancer is a solid tumor or metastatic cancer, wherein the solid tumor is bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, endometrial cancer, esophagus cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, Melanoma, ovarian, pancreatic, prostate or gastric cancer, preferably breast, lung, renal cell carcinoma (RCC), hepatocellular (HCC), melanoma, colorectal or endometrial cancer, particularly preferably primary Metastatic or metastatic non-small cell lung cancer (NSCLC), wherein the metastatic cancer is metastatic melanoma, metastatic colorectal cancer or metastatic endometrial cancer.
- RRCC renal cell carcinoma
- HCC hepatocellular
- NSCLC primary Metastatic or metastatic non-small cell lung cancer
- the subject thereof has relapsed or refractory cancer.
- hydroxyprogesterone caproate or the use of hydroxyprogesterone caproate and an additional therapeutic agent to treat cancer reduces tumor cell proliferation in the subject, and/or slows or stabilizes tumor growth in the subject.
- Figure 1 is a graph showing the growth trend of tumor volume after administration.
- Figure 2 shows tumor CD8 T cell infiltration (400X) in mice after administration.
- Figure 3 shows the densitometric analysis of CD8 staining in mouse tumor sections after administration, expressed as integral optical density (IOD)/area, where ** indicates p ⁇ 0.01 compared with the control group in the OHPC group.
- Anti-PD-L1 antibody was purchased from Rongchang Bio-Pharmaceutical (Yantai) Co., Ltd., batch number: RC98-1-A20170426, the concentration of the stock solution was 6.87 mg/ml, and the solvent was 0.9% sodium chloride solution. Before each administration, 0.9% sodium chloride injection was used to prepare a test drug solution containing Anti-PD-L1 at a concentration of 1 mg/ml.
- Hydroxyprogesterone caproate was purchased from Xianju County Hongyan Pharmaceutical Chemical Co., Ltd., powder. Before each administration, DMSO was used to dissolve the OHPC powder, and after the powder was completely dissolved, it was diluted with sesame oil to a test drug solution containing 4 mg/ml of OHPC.
- Mouse breast cancer 4T1 cells were purchased from Beijing Biositu Gene Biology Co., Ltd., and the cells were cultured in an incubator at 37°C with 5% CO 2 , and the medium composition was DMEM medium containing 10% inactivated fetal bovine serum.
- 4T1 cells were genetically modified by conventional methods to overexpress human PD-L1, and the cells were named 4T1-hPD-1.
- Balb/c mice SPF grade, female, 6-9 weeks old, weighing 16-22g. 4T1-hPD-1 cells were resuspended in PBS, and then subcutaneously inoculated on the right side of Balb/c mice at a concentration of 5 ⁇ 10 4 cells/0.1 ml in a volume of 0.1 ml/cell.
- appropriate mice were selected according to the tumor volume and weight of the mice, and they were equally divided into 4 experimental groups, with 8 mice in each group.
- the table shows:
- the administration volume is calculated as 10 ⁇ l/g according to the volume of the experimental animal.
- the body weight and tumor growth state of the experimental animals were continuously observed for 12 days. During the observation period, the tumor volume and the animal body weight were measured every week, and the measured values were recorded. After completing the observation, end the experiment.
- tumor volume 0.5 ⁇ long diameter ⁇ short diameter 2 .
- the adaptive feeding period and the experimental period were observed once a day, and the observation contents included but not limited to tumor nodule rupture, animal mental state, diet, etc.
- T0 the mean tumor volume of the treatment group on the 0th day of administration
- Vi the mean tumor volume of the solvent control group on the ith day of administration
- V0 The mean tumor volume of the solvent control group on day 0 of dosing.
- mice tumors were embedded in paraffin, and sliced for CD staining to compare the infiltration of CD8+ T cells in tumors between groups.
- Figure 1 shows a graph showing the growth trend of tumor volume after administration.
- 4T1 breast cancer is resistant to immunotherapy, so the anti-PD-L1 group did not show the effect of inhibiting tumor growth.
- OHPC alone also had no inhibitory effect.
- tumor growth was inhibited in the late stage, and the inhibition rate reached 30.7% at the end of the experiment on the 17th day.
- Table 2 The effect of the test article on the tumor volume of Balb/c mice transplanted with 4T1-hPD-L1 cells
- b Statistical comparison between the body weight of the administration group and the vehicle control group on the 17th day of group administration, t-test analysis.
- hydroxyprogesterone caproate can significantly enhance the infiltration of CD8+ T cells.
- Hydroxyprogesterone caproate can significantly enhance the infiltration of CD8+ T cells and enhance the anti-tumor activity of the monoclonal antibody Anti-PD-L1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供包括己酸羟孕酮和另一种治疗肿瘤的额外治疗剂,额外治疗剂优选针对PD-1或PD-L1的单克隆抗体。本发明还提供一种在需要时增加肿瘤浸润淋巴细胞(TIL)数量的方法和一种治疗有需要的受试者癌症的方法,包括向受试者提供己酸羟孕酮。
Description
交叉引用
本申请要求在2021年3月11日提交中国专利局、申请号为202110265778.5、发明名称为“包含己酸羟孕酮的抗肿瘤联合制剂及其用途”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
本发明涉及一种治疗肿瘤的药物组合物和一种治疗肿瘤的方法,特别涉及一种包括通过改善肿瘤微环境增强肿瘤治疗剂效果的药物组合物和通过联合用药治疗肿瘤的方法。
恶性肿瘤(癌症)是严重威胁人类健康的重大疾病,常规的治疗方法有手术、放疗、化疗和靶向治疗,但对于晚期肿瘤的效果非常有限且存在毒副作用大、耐受性差的问题。近几年,肿瘤免疫疗法取得了令人瞩目的临床效果,是一种通过激活人体自身免疫系统以对抗肿瘤的治疗手段,是目前最有潜力治愈恶性肿瘤的治疗手段。因此,肿瘤免疫疗法于2018年入选诺贝尔生理学或医学奖。
肿瘤微环境是癌症生物学的一个重要方面,其促成肿瘤发生、肿瘤进程和对治疗的应答。免疫系统的细胞和分子是肿瘤微环境的基本组成部分。肿瘤微环境的组成和特征变化很大并且对于确定抗肿瘤免疫应答很重要。例如,免疫系统的某些细胞,包括自然杀伤细胞、树突状细胞(DC)和效应T细胞,能够驱动强有力的抗肿瘤应答。然而,肿瘤细胞常常诱导免疫抑制性微环境,其有利于发展免疫细胞的免疫抑制性群体,如髓源性抑制细胞和调节性T细胞。
免疫检查点抑制剂作为肿瘤免疫疗法的代表,可通过阻断肿瘤微环境中的免疫抑制信号,恢复免疫细胞的功能发挥抗肿瘤作用。其中,研究最为深入、应用最成熟的免疫检查点是细胞程序性死亡受体1(PD-1)、程序性死亡配体1和2(PD-L1/L2)、细胞毒性T细胞抗原4(CTLA-4),以及淋巴细胞激活基因3(LAG-3)、T细胞免疫球蛋白黏蛋白3(TIM-3)、T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT)和T细胞激活V区免疫球蛋白抑制剂(VISTA)等(RandophJ.Nolle,Science,2020)。
在肿瘤微环境中,PD-1和/或PD-L1在来自许多不同肿瘤类型的大部分肿瘤浸润淋巴细胞(TIL)中高度表达,并抑制局部效应免疫应答包括肺癌、肝癌、卵巢癌、宫颈癌、皮肤癌、结肠癌、神经胶质瘤、膀胱癌、乳腺癌、肾癌、食道癌、胃癌、口腔鳞状上皮细胞癌、泌尿道上皮细胞癌和胰腺癌以及头部和颈部的肿瘤。PD-1和/或PD-L1抗体能够阻断肿瘤细胞上的PD-L1与活化T细胞表面的抑制性受体PD-1结合,从而活化肿瘤特异性T细胞,重建免疫系统对肿瘤细胞的杀伤作用。然而,由于肿瘤具有极大的异质性和遗传不稳定性,其发病机制复杂,肿瘤组织中存在多种内源性和外源性的免疫抵抗机制,PD-1抗体只有20%左右的临床反应率。
发明人通过研究发现,不仅PD-1抗体,其他抗体乃至各种肿瘤治疗剂在临床中都表现出了与体外试验较大的差异,一个重要的原因是肿瘤周围具有适合癌细胞存活和增殖的微环境,导致例如药物难以抵达靶点、免疫细胞难以进入肿瘤组织内部杀灭癌细胞等问题。
17α-羟基孕甾-4-烯-3,20-二酮己酸酯,也称己酸羟孕酮、17-羟基孕酮己酸酯、17-HPC、17-OHPC、OHPC,英文名:Hydroxyprogesterone Caproate,CAS No.:630-56-8,临床上用于治疗习惯性流产、月经不调、子宫内膜异位症、功能性子宫出血等。
发明内容
根据本发明的一个方面,提供了一种药物组合物,包括己酸羟孕酮和另一种治疗肿瘤的额外治疗剂。
可选地,另一种治疗肿瘤的额外治疗剂选自:化疗剂、靶向治疗剂、激素治疗剂、细胞治疗剂、溶瘤性病毒剂或抗体,特别是免疫检查点抑制剂。
可选地,所述免疫检查点抑制剂选自PD-L1,PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,SLAM或其组合的抑制剂;优选的,所述免疫检查点抑制剂是单克隆抗体,特别优选针对PD-1或PD-L1的单克隆抗体。
可选地,所述额外治疗剂选自阿特珠单抗,阿维鲁单抗,德瓦鲁单抗,卡瑞利珠单抗,西米单抗,伊匹单抗,纳武单抗,派姆单抗,信迪利单抗,替雷利珠单抗,特瑞普利单抗,替西木单抗、RC98。
根据本发明的另一个方面,还提供一种抗肿瘤药物,其包含上述的包括己酸羟孕酮和另一种治疗肿瘤的额外治疗剂的药物组合物,和任选地一种或者多种药学上可接受的辅料。
可选地,抗肿瘤药物的剂型选自注射剂,口服制剂或外用制剂;优选注射剂或口服制剂;特别优选注射剂。所述注射剂选自注射液或粉针剂;口服制剂选自片剂、溶液剂、胶囊剂、散剂、丸剂、颗粒剂、糖浆剂、混悬剂或者口服缓控释制剂;外用制剂选自软膏剂、喷剂或贴剂。
可选地,额外治疗剂含量为单独使用时治疗有效量的10%-100%。在每日一片/剂的剂型中,每片/剂己酸羟孕酮的含量为100-1000mg,在每日使用m片/剂的剂型中,每片/剂己酸羟孕酮的含量为(100-1000mg)/m,在n日使用一片剂的剂型中,每片/剂己酸羟孕酮的含量为n×(100-1000mg)。
可选地,所述药学上可接受的辅料选自药学上可接受的溶剂、增溶剂、助溶剂、乳化剂、着色剂、粘合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗粘合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂、反絮凝剂、助滤剂、释放阻滞剂、高分子骨架材料和成膜材料中的至少一种。
根据本发明的另一方面,本发明提供了一种在需要时增加肿瘤浸润淋巴细胞(TIL)数量的方法,包括向受试者提供己酸羟孕酮。
可选地,其TIL群体包含CD8+T细胞,CD4+T细胞,B细胞,自然杀伤(NK)细胞,树突细胞(DC),M1巨噬细胞或其组合的群体,优选表达TH1表型的T细胞。
可选地,其中TIL数量在肿瘤微环境(TME)中增加和/或在肿瘤组织中增加。
根据本发明的另一方面,本发明提供了一种治疗有需要的受试者癌症的方法,包括向受试者提供己酸羟孕酮。
可选地,包括向受试者提供除己酸羟孕酮以外的治疗癌症的额外治疗剂。
可选地,其额外治疗剂选自化疗剂、靶向治疗剂、激素治疗剂、细胞治疗剂、溶瘤性病毒剂或抗体。
可选地,其所述的额外治疗剂选自免疫治疗剂。
可选地,其所述额外治疗剂选自免疫检查点抑制剂。
可选地,其中免疫检查点抑制剂选自PD-L1,PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,SLAM的抑制剂,优选针对PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2, SLAM或其组合的单克隆抗体,特别优选针对PD-L1或PD-1的单克隆抗体。
可选地,其中所述额外治疗剂选自阿特珠单抗,阿维鲁单抗,德瓦鲁单抗,卡瑞利珠单抗,西米单抗,伊匹单抗,纳武单抗,派姆单抗,信迪利单抗,替雷利珠单抗,特瑞普利单抗,替西木单抗或RC98。
可选地,其中受试者具有较高的PD-L1或PD-1表达。
可选地,其作为一线或二线治疗方法施用。
可选地,其己酸羟孕酮可以在施用额外治疗剂之前、同时或之后施用于受试者。
可选地,其受试者患有原发性或转移性癌症。其所述癌症为实体瘤或转移癌,其中实体瘤是膀胱癌、骨癌、脑癌、乳腺癌、结直肠癌、子宫内膜癌、食道癌、眼癌、头颈癌、肾癌、肺癌、黑色素瘤、卵巢癌、胰腺癌、前列腺癌或胃癌,优选乳腺癌、肺癌、肾细胞癌(RCC)、肝细胞癌(HCC)、黑色素瘤、结直肠癌或子宫内膜癌,特别优选原发性或转移性非小细胞肺癌(NSCLC),其所述转移癌是转移黑色素瘤,转移结直肠癌或转移性子宫内膜癌。
可选地,其受试者患有复发性癌症或难治性癌症。
可选地,使用己酸羟孕酮或使用己酸羟孕酮和治疗癌症的额外治疗剂降低了受试者中肿瘤细胞的增值,和/或减缓或稳定了受试者的肿瘤生长。
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为给药后肿瘤体积增长趋势图。
图2为给药后小鼠肿瘤CD8T细胞浸润(400X)。
图3为给药后小鼠肿瘤切片CD8染色光密度分析,以积分光密度值(IOD)/面积(area)表示,其中**表示OHPC组与对照组相比p<0.01。
提供下述实施例是为了更好地进一步理解本发明,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者,按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
实验例1
1、受试药物与试剂
抗体Anti-PD-L1购自荣昌生物制药(烟台)有限公司,批号:RC98-1-A20170426,储存液浓度为6.87mg/ml,溶媒为0.9%氯化钠溶液。每次给药前,采用0.9%的氯化钠注射液配制成含Anti-PD-L1的浓度为1mg/ml的受试药物溶液。
己酸羟孕酮(OHPC)购自仙居县鸿雁医药化工有限公司,粉末。每次给药前,采用DMSO溶解OHPC粉末,待粉末完全溶解后,用芝麻油稀释到含OHPC浓度为4mg/ml的受试药物溶液。
2、动物分组、造模及给药
(1)细胞培养
小鼠乳腺癌4T1细胞购自北京百奥赛图基因生物有限公司,细胞培养在37℃、5%CO
2的培养箱中培养,培养基成分为含有10%灭活胎牛血清的DMEM培养基。本实验使用常规方法对4T1细胞进行基因改造,使其过量表达人源PD-L1,该细胞被命名为4T1-hPD-1。
(2)肿瘤细胞的接种、分组与给药。
Balb/c小鼠,SPF级,雌性,6-9周龄,体重16-22g。采用PBS重悬4T1-hPD-1细胞,然后以5×10
4个/0.1ml浓度,0.1ml/只体积接种于Balb/c小鼠的右侧皮下。当平均肿瘤体积达到约100mm
3时,根据小鼠肿瘤体积和重量选择合适的小鼠入组,平均分配到4个实验组中,每组8只,分别当天开始给药,具体给药方案如下表所示:
表1给药方案
其中,a:给药体积依实验动物体积按10μl/g计算。
末次给药后,对实验动物体重及肿瘤生长状态继续观察12天,观察期间,每周测量肿瘤体积及动物体重,并记录测量值。完成观察后,结束实验。
3、检测指标
(1)肿瘤体积
分组后每周使用游标卡尺对肿瘤体积进行2次测量,安乐死前测量肿瘤体积,测量肿瘤的长径和短径,其体积计算公式为:肿瘤体积=0.5×长径×短径
2。
(2)体重检测
接种、分组(即首次给药前)、给药期间每周2次、安乐死前称取动物体重。
(3)一般临床观察
适应性饲养期和实验期间每天观察1次,观察内容包括但不限于肿瘤结节破溃情况、动物精神状态、饮食情况等。
4、药物评价指标
(1)肿瘤体积抑制率(TGl
TV)
TGl
TV(%)=[1-(Ti-T0)/(Vi-V0)]×100%;
其中,Ti:治疗组在给药第i天的肿瘤体积均值,T0:治疗组在给药第0天的肿瘤体积均值;Vi:溶剂对照组在给药第i天的肿瘤体积均值,V0:溶剂对照组在给药第0天的肿瘤体积均值。
(2)肿瘤组织CD8+T细胞浸润
实验结束后,取小鼠肿瘤石蜡包埋,切片进行CD染色,比较组间肿瘤中CD8+T细胞浸润。
5、数据采集和统计学分析
测定和观察的原始数据进行记录,基于原始数据进行分析处理,结果分析用平均数和标准误表示(Mean±SEM)。同时对肿瘤体积进行统计学分析,P<0.05认为有显著性差异。结果分析时同时考虑统计学意义和生物学意义。
6、实验结果
(1)肿瘤体积抑制结果
图1示出了给药后肿瘤体积增长趋势图。由图1可以看出,4T1乳腺癌对免疫治疗耐受,因此anti-PD-L1组没有显示出抑制肿瘤生长的效果。OHPC单独给药也没有抑制效果。但在anti-PD-L1和OHPC联用组,肿瘤生长后期受到抑制,第17天实验结束时候抑制率达到30.7%。
各组肿瘤体积和肿瘤肿瘤体积抑制率结果列于表2。
表2受试品对4T1-hPD-L1细胞移植Balb/c小鼠肿瘤体积的影响
注:a:平均数±标准误差;
b:给药组体重与Vehicle对照组体重在分组给药第17天统计学比较,t-test分析。
(2)肿瘤组织CD8+T细胞浸润
参见说明书附图图2和图3,己酸羟孕酮能够明显增强CD8+T细胞浸润。
7、实验结论
己酸羟孕酮能够明显增强CD8+T细胞浸润,能够增强单抗药物Anti-PD-L1的抗肿瘤活性。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (27)
- 一种药物组合物,其特征在于,包括己酸羟孕酮和另一种治疗肿瘤的额外治疗剂。
- 根据权利要求1所述的药物组合物,其特征在于,另一种治疗肿瘤的额外治疗剂选自:化疗剂、靶向治疗剂、激素治疗剂、细胞治疗剂、溶瘤性病毒剂或抗体。
- 根据权利要求1或2所述的药物组合物,其特征在于,所述额外治疗剂是免疫检查点抑制剂。
- 根据权利要求3所述的药物组合物,其特征在于,所述免疫检查点抑制剂是针对PD-L1,PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,或SLAM的抑制剂,优选针对PD-1或PD-L1的单克隆抗体。
- 根据权利要求4所述的药物组合物,其特征在于,所述额外治疗剂选自阿特珠单抗,阿维鲁单抗,德瓦鲁单抗,卡瑞利珠单抗,西米单抗,伊匹单抗,纳武单抗,派姆单抗,信迪利单抗,替雷利珠单抗,特瑞普利单抗,替西木单抗、RC98。
- 一种抗肿瘤药物,其包含权利要求1-5中任一项所述的药物组合物,和任选地一种或者多种药学上可接受的辅料。
- 根据权利要求6所述的抗肿瘤药物,其特征在于,抗肿瘤药物的剂型选自注射剂,口服制剂或外用制剂;优选注射剂或口服制剂;特别优选注射剂。
- 根据权利要求7所述的抗肿瘤药物,其特征在于,所述注射剂选自注射液或者粉针剂;口服制剂选自片剂、溶液剂、胶囊剂、散剂、丸剂、颗粒剂、糖浆剂、混悬剂或者口服缓控释制剂;外用制剂选自软膏剂、喷剂或者贴剂。
- 根据权利要求6-8中任一项所述的抗肿瘤药物,其特征在于,额外治疗剂含量为单独使用时治疗有效量的10%-100%。
- 根据权利要求6-9中任一项所述的抗肿瘤药物,其特征在于,在每日一片/剂的剂型中,每片/剂己酸羟孕酮的含量为100-1000mg,在每日使用m片/剂的剂型中,每片/剂己酸羟孕酮的含量为(100-1000mg)/m,在n日使用一片剂的剂型中,每片/剂己酸羟孕酮的含量为n×(100-1000)mg。
- 一种在需要时增加肿瘤浸润淋巴细胞(TIL)数量的方法,包括向受试者提供己酸羟孕酮。
- 根据权利要求11所述的方法,其特征在于,TIL群体包含CD8+T细胞,CD4+T细胞,B细胞,自然杀伤(NK)细胞,树突细胞(DC),M1巨噬细胞或其组合的群体, 优选表达TH1表型的T细胞。
- 根据权利要求11或12所述的方法,其特征在于,其中TIL数量在肿瘤微环境(TME)中增加和/或在肿瘤组织中增加。
- 一种治疗有需要的受试者癌症的方法,其特征在于,包括向受试者提供己酸羟孕酮。
- 根据权利要求11-14中任一项所述的方法,其特征在于,还包括向受试者提供除己酸羟孕酮以外的治疗癌症的额外治疗剂。
- 根据权利要求15所述的方法,其特征在于,所述额外治疗剂选自化疗剂、靶向治疗剂、激素治疗剂、细胞治疗剂、溶瘤性病毒剂或抗体。
- 根据权利要求15所述的方法,其特征在于,所述额外治疗剂选自免疫治疗剂。
- 根据权利要求17所述的方法,其特征在于,所述额外治疗剂选自免疫检查点抑制剂。
- 根据权利要求18所述的方法,其特征在于,所述免疫检查点抑制剂选自PD-L1,PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,SLAM的抑制剂,优选针对PD-1,PD-L2,CTLA-4,LAG3,B7-H3,KIR,CD137,PS,TFM3,CD52,CD30,CD20,CD33,CD27,OX40,GITR,ICOS,BTLA(CD272),CD160,2B4,LAIR1,TIGHT,LIGHT,DR3,CD226,CD2,SLAM或其组合的单克隆抗体,特别优选针对PD-L1或PD-1的单克隆抗体。
- 根据权利要求15-19中任一项所述的方法,其特征在于,所述额外治疗剂选自阿特珠单抗,阿维鲁单抗,德瓦鲁单抗,卡瑞利珠单抗,西米单抗,伊匹单抗,纳武单抗,派姆单抗,信迪利单抗,替雷利珠单抗,特瑞普利单抗,替西木单抗或RC98。
- 根据权利要求15-20中任一项所述的方法,其特征在于,受试者具有较高的PD-L1或PD-1表达。
- 根据权利要求11-21中任一项所述的方法,其作为一线或二线治疗方法施用。
- 根据权利要求15-22中任一项所述的方法,其己酸羟孕酮在施用额外治疗剂之前、同时或之后施用于受试者。
- 根据权利要求11-23中任一项所述的方法,其受试者患有原发性或转移性癌症。
- 根据权利要求24所述的方法,其所述癌症为实体瘤或转移癌,其中实体瘤是膀胱癌、骨癌、脑癌、乳腺癌、结直肠癌、子宫内膜癌、食道癌、眼癌、头颈癌、肾癌、 肺癌、黑色素瘤、卵巢癌、胰腺癌、前列腺癌或胃癌,优选乳腺癌、肺癌、肾细胞癌(RCC)、肝细胞癌(HCC)、黑色素瘤、结直肠癌或子宫内膜癌,特别优选原发性或转移性非小细胞肺癌(NSCLC),其所述转移癌是转移黑色素瘤,转移结直肠癌或转移性子宫内膜癌。
- 根据权利要求14-25中任一项所述的方法,其受试者患有复发性癌症或难治性癌症。
- 根据权利要求14-26中任一项所述的方法,其使用己酸羟孕酮或使用己酸羟孕酮和治疗癌症的额外治疗剂降低了受试者中肿瘤细胞的增值,和/或减缓或稳定了受试者的肿瘤生长。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22766372.1A EP4309658A1 (en) | 2021-03-11 | 2022-03-11 | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110265778.5A CN115068487B (zh) | 2021-03-11 | 2021-03-11 | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 |
CN202110265778.5 | 2021-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022188850A1 true WO2022188850A1 (zh) | 2022-09-15 |
Family
ID=83226303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/080275 WO2022188850A1 (zh) | 2021-03-11 | 2022-03-11 | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4309658A1 (zh) |
CN (1) | CN115068487B (zh) |
WO (1) | WO2022188850A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1623550A (zh) * | 2003-12-04 | 2005-06-08 | 张伟 | 己酸羟孕酮口服制剂和用途 |
WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
WO2017053823A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
CN108159056A (zh) * | 2018-02-09 | 2018-06-15 | 上海礼璞生物医药科技有限公司 | 孕激素在制备组蛋白去乙酰化酶抑制剂和气道周围胶原沉积抑制剂药物中的应用及抑制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014339816B2 (en) * | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
US10335388B2 (en) * | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
WO2017019767A1 (en) * | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
WO2018026742A1 (en) * | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
CN108159058A (zh) * | 2018-02-09 | 2018-06-15 | 上海礼璞生物医药科技有限公司 | 黄体酮在制备抑制HIF-1α表达的药物中的用途 |
-
2021
- 2021-03-11 CN CN202110265778.5A patent/CN115068487B/zh active Active
-
2022
- 2022-03-11 WO PCT/CN2022/080275 patent/WO2022188850A1/zh active Application Filing
- 2022-03-11 EP EP22766372.1A patent/EP4309658A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1623550A (zh) * | 2003-12-04 | 2005-06-08 | 张伟 | 己酸羟孕酮口服制剂和用途 |
WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
WO2017053823A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
CN108159056A (zh) * | 2018-02-09 | 2018-06-15 | 上海礼璞生物医药科技有限公司 | 孕激素在制备组蛋白去乙酰化酶抑制剂和气道周围胶原沉积抑制剂药物中的应用及抑制剂 |
Non-Patent Citations (6)
Title |
---|
BAO SHENGYING , SHI YIFU: "Study on the related factors of curative effect of progesterone caproate on endometrial cancer", CURRENT ADVANCES IN OBSTETRICS AND GYNECOLOGY, no. 2, 15 May 1998 (1998-05-15), pages 151 - 152, XP055966687, ISSN: 1004-7379, DOI: 10.13283/j.cnki.xdfckjz.1998.02.017 * |
LU HUIJUAN; DU XINGU; ZHANG XIYIN: "Role of hydroxyprogesterone caproate, tamoxifen and aminoglutethemide in endometrial careinoma", CURRENT ADVANCES IN OBSTETRICS AND GYNECOLOGY, vol. 3, no. 3, 15 August 1994 (1994-08-15), pages 1 - 7, XP055966215, ISSN: 1004-7379, DOI: 10.13283/j.cnki.xdfck.jz.1994.03.002 * |
no. 630-56-8 |
ONSRUD, M.: "Adjuvant hydroxyprogesterone caproate in stage I endometrial carcinoma: Changes in numbers and reactivities of some blood lymphocyte subpopulations", GYNECOLOGIC ONCOLOGY, vol. 14, no. 3, 1 December 1982 (1982-12-01), GB , pages 355 - 364, XP026239109, ISSN: 0090-8258, DOI: 10.1016/0090-8258(82)90110-X * |
RANDOLPH J. NOLLE, SCIENCE, 2020 |
曹海敬等 (CAO, HAIJING ET AL.): "子宫内膜癌治疗药物的研究进展 (Non-official translation: Research Progress of Drugs for Endometrial Cancer)", 中国药理学会第十一届全国基础与临床生殖药理学术研讨会暨生殖药理新技术与新方法培训班论文汇编 (NON-OFFICIAL TRANSLATION: COMPILATION OF PAPERS OF THE 11ST NATIONAL SYMPOSIUM ON BASIC AND CLINICAL REPRODUCTIVE PHARMACOLOGY AND REPRODUCTIVE PHARMACOLOGY NEW TECHNOLOGY AND METHOD TRAINING COURSE OF T, 20 September 2019 (2019-09-20) * |
Also Published As
Publication number | Publication date |
---|---|
EP4309658A1 (en) | 2024-01-24 |
CN115068487A (zh) | 2022-09-20 |
CN115068487B (zh) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chu | Physicians' Cancer Chemotherapy Drug Manual 2017 | |
Morimoto et al. | Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells | |
US10532073B2 (en) | RAR selective agonists in combination with immune modulators for cancer immunotherapy | |
CN110996952A (zh) | 用于治疗癌症的方法 | |
US10821127B2 (en) | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient | |
Cai et al. | Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression | |
US12070443B2 (en) | Methods of treating and preventing breast cancer with S-equol | |
CN106604933A (zh) | 抗pd‑l1抗体及其诊断用途 | |
JP7239463B2 (ja) | がん免疫療法のための組成物および方法 | |
Siu et al. | Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment | |
US20190240258A1 (en) | Pd-1 car nk-92 cell and preparation method and use thereof | |
JP2020505433A (ja) | Hsp90阻害剤を使用してがんを治療するための方法 | |
US20220175787A1 (en) | Patient selection for enhancement of anti-tumor immunity in cancer patients | |
Attili et al. | Strategies to overcome resistance to immune checkpoint blockade in lung cancer | |
WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
WO2020015703A9 (zh) | 喹啉衍生物与抗体的药物组合 | |
WO2019122941A1 (en) | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule | |
Kong et al. | A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy | |
Borrie et al. | T Lymphocyte–Based Cancer Immunotherapeutics | |
Glorieux et al. | Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer | |
Blaauboer et al. | Type I interferons in pancreatic cancer and development of new therapeutic approaches | |
WO2022188850A1 (zh) | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 | |
US20220184082A1 (en) | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab | |
WO2019178438A1 (en) | Abbv-621 in combination with anti-cancer agents for the treatment of cancer | |
CN108779091A (zh) | 色烯化合物和第二活性剂的组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22766372 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022766372 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022766372 Country of ref document: EP Effective date: 20231011 |